Refine
Has Fulltext
- yes (98)
Is part of the Bibliography
- yes (98)
Year of publication
- 2015 (98) (remove)
Document Type
- Journal article (61)
- Doctoral Thesis (37)
Keywords
- cancer (4)
- membrane proteins (4)
- Aspergillus fumigatus (3)
- Vaccinia-Virus (3)
- biodiversity (3)
- gene (3)
- honeybee (3)
- in vitro (3)
- mushroom body (3)
- olfaction (3)
- Angiogenese (2)
- Biene (2)
- Biologische Uhr (2)
- CD8 (2)
- Candida albicans (2)
- Dendritische Zelle (2)
- Drosophila (2)
- Drosophila melanogaster (2)
- ELISPOT (2)
- Humangenetik (2)
- Inhibition (2)
- Krebs <Medizin> (2)
- Mesenchymzelle (2)
- Myc (2)
- RNA-Seq (2)
- Taufliege (2)
- active zone (2)
- avoidance learning (2)
- bees (2)
- bumblebees (2)
- butterflies (2)
- cytoskeleton (2)
- dendritic cells (2)
- ecosystem services (2)
- evolution (2)
- expression (2)
- fluorescent probes (2)
- growth (2)
- insects (2)
- leaf-cutting ants (2)
- localization microscopy (2)
- melanoma (2)
- metabolism (2)
- microarray (2)
- microglomeruli (2)
- neurotransmitter release (2)
- next generation sequencing (2)
- resistance (2)
- synaptic plasticity (2)
- virulence (2)
- "-omics" (1)
- 2-APB (1)
- 3-dimensional structure (1)
- ANOVA (1)
- Acromyrmex ambiguus (1)
- Acyrthosiphon pisum (1)
- Adenosin (1)
- Adipogenesis (1)
- Amyotrophe Lateralsklerose (1)
- Angiogenesis (1)
- Antigen CD8 (1)
- Apoptose (1)
- Apoptosis (1)
- Arachidonsäure (1)
- Arbeitsteilung (1)
- Astrozyten (1)
- Aurora-A (1)
- Ausbreitung (1)
- Australian stingless bees (1)
- Axonal degeneration (1)
- BH3 domains (1)
- Bakterielle Infektion (1)
- Bauchspeicheldrüsenkrebs (1)
- Bcl-2 proteins (1)
- Behandlungsoption (1)
- Bienen <Familie> (1)
- BioID (1)
- Bone marrow stromal cell (BMSC) (1)
- Bruchpilot (1)
- C. elegans (1)
- CD39 (1)
- CD4 (1)
- CD4+T cells (1)
- CD73 (1)
- CD8+T cells (1)
- CNTF (1)
- CTL function (1)
- CaMKII (1)
- Ca\(^{2+}\) channels (1)
- Caenorhabditis elegans (1)
- ChIP-sequencing (1)
- Chlamydia (1)
- Chlamydia trachomatis (1)
- Ciliary neurotrophic factor (1)
- Circadian clock (1)
- Circadiane Rhythmen (1)
- Co-option (1)
- Costa Rica (1)
- Cynoglossus semilaevis (1)
- Cytotoxizität (1)
- DMRT1 (1)
- DNA Mismatch repair (1)
- DNA barcoding (1)
- DNA damage (1)
- DNA methylation (1)
- DNA-Sequenz (1)
- DNA-binding proteins (1)
- DNS-Reparatur (1)
- Darmflora (1)
- Demökologie (1)
- Diabetic polyneuropathy (1)
- Diagnostik (1)
- Dickdarmkrebs (1)
- Differentiation (1)
- Division of labor (1)
- EPC (1)
- Eierstockkrebs (1)
- Eierstocktumor (1)
- Eisenoxidnanopartikel (1)
- Elongation (Transkription) (1)
- Endothel (1)
- Epigenetik (1)
- Epimutationen (1)
- Erbkrankheit (1)
- FANCO (1)
- Fanconi Anämie (1)
- Fettgewebsstammzellen (1)
- Fettzelle (1)
- Fibroblastenwachstumsfaktor (1)
- Foxp3 (1)
- Fragmentierung (1)
- Französische Feldwespe (1)
- Gen (1)
- Genetic engineering (1)
- Genexpression (1)
- Geschützte Natur (1)
- Glioblastom (1)
- Governance (1)
- HHblits (1)
- HIF-1α (1)
- HLA-G (1)
- Habitat (1)
- Halobacterium halobium (1)
- HeLa cells (1)
- Heuschrecken <Überfamilie> (1)
- Homoptera aphididae (1)
- Honeybee (1)
- Honigbiene (1)
- Host cell death (1)
- Human Host (1)
- Hydrogel (1)
- Hydrogele (1)
- Hymenoptera (1)
- Hypoxie (1)
- Hämatopoese (1)
- I-tasser (1)
- IFN-γ (1)
- III adenylyl cyclases (1)
- III secretion (1)
- III secretion system (1)
- IL-17 (1)
- IL-2 (1)
- IL-4 (1)
- IL-5 (1)
- ITS2 (1)
- Immune (1)
- Immunologie (1)
- Immunsuppression (1)
- Immunsystem (1)
- Infertilität (1)
- Inhibitor (1)
- Innere Uhr (1)
- Intracellular replication (1)
- Johnstons organ (1)
- Kehlkopf (1)
- Killerzelle (1)
- Knochenregeneration (1)
- Knockout <Molekulargenetik> (1)
- LC-MS/MS (1)
- LINC complex (1)
- Landouzy-Déjerine-Atrophie (1)
- Landschaftsökologie (1)
- Laufkäfer (1)
- Legionella (1)
- Lernen (1)
- MAP-Kinase (1)
- MAPK (1)
- MITF (1)
- MORN-repeat (1)
- MRSA (1)
- MSC (1)
- MYCN (1)
- MYCN-amplified (1)
- Magerrasen (1)
- Maus (1)
- Melanom (1)
- Melanomzellen (1)
- Mesenchymale Stammzelle (1)
- Messenger-RNP (1)
- Messenger-RNS (1)
- Metagenom (1)
- Metastase (1)
- Mikroglia (1)
- Mismatch (1)
- Mitogen-aktivierte Proteinkinase (1)
- Miz1 (1)
- Molekularbiologie (1)
- Molekulargenetik (1)
- Mosaik (1)
- Motoneuron (1)
- Motoneuronenerkrankung (1)
- Motor nerve biopsy (1)
- Multiples Myelom (1)
- Mutation (1)
- Myatrophische Lateralsklerose (1)
- Myc Transcription (1)
- Mycobacterium (1)
- Mycobacterium tuberculosis (1)
- Myotonische Dystrophie (1)
- N-Myc (1)
- NF-κB (1)
- NFAT (1)
- NGS (1)
- NVP-BEZ235 (1)
- Nestbau (1)
- Neuroblastom (1)
- Neuroblastoma (1)
- Neuronal plasticity (1)
- Neuronale Plastizität (1)
- Neuropathy (1)
- Neurotrophic factors (1)
- Next Generation Sequencing (1)
- Nisthilfe (1)
- Normal Distribution (1)
- Oncolytic Vaccinia Virus Therapy (1)
- Onkolyse (1)
- Onkolytische Vaccinia Virustherapie (1)
- Osteogenesis (1)
- Osteoporose (1)
- Pan-Raf-Inhibition (1)
- Participation (1)
- Period (1)
- Peroxiredoxin (1)
- Peroxiredoxin 6 (1)
- Phagosom (1)
- Phagosomal escape (1)
- Phagozytose (1)
- Pheromon (1)
- Pheromon Kommunikation (1)
- Pheromon communication (1)
- Phosphorylierung (1)
- Plasmozytom (1)
- Polistes (1)
- Populationsgenetik (1)
- Prostaglandin E2 (1)
- Proteasomaler Abbau (1)
- Protected Area (1)
- RAD51C (1)
- RNA binding proteins (1)
- RNAi (1)
- RNS-Interferenz (1)
- RNS-Polymerase II (1)
- Raf-Kinasen (1)
- Rapsanbau (1)
- Regulatorischer T-Lymphozyt (1)
- Remission (1)
- Repression (1)
- Reversion (1)
- SOX9 (1)
- STAT3 (1)
- SUN domain proteins (1)
- Salmonella (1)
- Salmonella-containing vacuole (SCV) (1)
- Sekundärwald (1)
- Shaggy (1)
- Simkania (1)
- Simkania negevensis (1)
- South Korea (1)
- Squalius alburnoides (1)
- Stammzelle (1)
- Staphylococcus aureus (1)
- Sterilität (1)
- Strahlensensibilisator (1)
- Strahlentherapie (1)
- T cells (1)
- T-cells (1)
- TLR7 (1)
- TLR8 (1)
- TbMORN1 (1)
- Therapie (1)
- Therapy (1)
- Thermoregulation (1)
- Thrombozyt (1)
- Timeless (1)
- Tissue Engineering (1)
- Toll-like-Rezeptoren (1)
- Transkription <Genetik> (1)
- Transkriptionsfaktor (1)
- Trypanosoma brucei (1)
- Tumorerkrankungen (1)
- Tumorzelle (1)
- Ubiquitinierung (1)
- V-antigen (1)
- Vascular endothelial Growth Factor (1)
- Vorläuferzelle (1)
- W Arly Pendjari WAP (1)
- WH2 domain (1)
- Wespen (1)
- West Africa (1)
- Westafrika (1)
- Wilms tumour (1)
- Wirtszelle (1)
- Xiphophorus (1)
- Y chromosome (1)
- Yersinia enterocolitica (1)
- Zelltod (1)
- \(\alpha\)-latrotoxin (1)
- abundance (1)
- acromyrmex ambiguus (1)
- actin nucleation (1)
- action potentials (1)
- acts downstream (1)
- adaptive growth (1)
- adipocytes (1)
- agent-based model (1)
- agricultural intensification (1)
- agricultural landscapes (1)
- agroecosystems (1)
- algorithm (1)
- alignment (1)
- alpha-toxin (1)
- alzheimers disease (1)
- angeborenes Immunsystem (1)
- angiogenesis (1)
- animal migration (1)
- animal sexual behavior (1)
- antagonist (1)
- antennal lobe (1)
- antimicrobial peptides (1)
- apis mellifera (1)
- apixaban (1)
- apoptosis (1)
- arachidonic acid (1)
- armyworm Lepidoptera (1)
- assemblages (1)
- axonaler Transport (1)
- bacterial invasion (1)
- bacterial pathogens (1)
- bacteriorhodopsin (1)
- bacterium Legionella pneumophila (1)
- bagworms Lepidoptera (1)
- balance hypothesis (1)
- bark beetles (1)
- bax (1)
- beetle horns (1)
- behavior (1)
- behavioral conditioning (1)
- beta-catenin (1)
- beta-diveristy (1)
- beta-lactamase inhibition (1)
- biased dispersal (1)
- binding (1)
- biodiversity conservation (1)
- biodiversity-ecosystem functioning (1)
- biofilm formation (1)
- bioinformatics and computational biology (1)
- biological control (1)
- biological pest control (1)
- biology (1)
- biomaterial surfaces (1)
- body-size (1)
- bone regeneration (1)
- cabbage Brassica oleracea var. capitata (1)
- calcareous grassland (1)
- calpain (1)
- camponotus floridanus (1)
- candida genome database (1)
- capture-mark-recapture (1)
- carbon dioxide avoidance (1)
- carbonaria (1)
- carpenter ant (1)
- carrying capacity (1)
- cell fate (1)
- cell membranes (1)
- cell proliferation (1)
- cell size (1)
- cell wall (1)
- cells (1)
- cellular camp (1)
- cellular senescence (1)
- centrality (1)
- channelrhodopsin-2 (1)
- chlamydia (1)
- chlamydia infection (1)
- chlamydia trachomatis (1)
- chondrosarcoma (1)
- chordotonal organs (1)
- circadian rhythms (1)
- climate change (1)
- clock reproduction ecology (1)
- co-immunoprecipitation (1)
- coincidence (1)
- color discrimination (1)
- communities (1)
- community composition (1)
- community functional-responses (1)
- compartment boundary (1)
- complex (1)
- complex networks (1)
- complex traits (1)
- compound eye (1)
- computational prediction (1)
- computational systems biology (1)
- contributes (1)
- control profiles (1)
- copy number (1)
- crop harvest (1)
- crystal structure (1)
- cuticular profiles (1)
- cytokine profiling (1)
- cytokines (1)
- cytokinesis (1)
- c‐Myc (1)
- dSTORM (1)
- database (1)
- day length (1)
- death pathway sar locus (1)
- decay (1)
- decline (1)
- defense and evasion strategies (1)
- defenses (1)
- degradation (1)
- determination locus (1)
- determining genes (1)
- diagnostic accuracy (1)
- differentially expressed genes (1)
- differentiation (1)
- diffraction limit (1)
- direct oral anticoagulants (1)
- direct thrombin inhibitor (1)
- discovery (1)
- dispersal (1)
- disruption project (1)
- diversity (1)
- division of labor (1)
- domain (1)
- drosophila larvae (1)
- dynamics (1)
- ecology (1)
- electrolytes (1)
- encephalitis dementia (1)
- endocytic multivesicular bodies (1)
- endoplasmic reticulum (1)
- endothelial cells (1)
- enteric pathogens (1)
- enterica serovar Typhimurium (1)
- envelopment (1)
- epithelial cells (1)
- eucalyptus (1)
- eukaryotic gene expression (1)
- european beech forests (1)
- european countries (1)
- excitation-secretion coupling (1)
- exome (1)
- expression analysis (1)
- factor B (1)
- factor XA inhibitor (1)
- family (1)
- fish (1)
- fishes Xiphophorus (1)
- flagellar motility (1)
- flies (1)
- flow (1)
- flowers (1)
- fluorescence microscopy (1)
- format (1)
- fruit set (1)
- functional analysis (1)
- functional modules (1)
- fungal pathogens (1)
- gain (1)
- gastrointestinal cancer (1)
- gating (1)
- gene expression (1)
- gene ontology (1)
- gene regulator agr (1)
- genetics (1)
- genome (1)
- genome browser (1)
- genome cells (1)
- genus Xiphophorus (1)
- geprägte Gene (1)
- glial cells (1)
- glycerol (1)
- gonopodium (1)
- growth and differentiation factor 5 (1)
- guides (1)
- habitats (1)
- hearing (1)
- herbivores (1)
- herbivorous insects (1)
- heterogamety (1)
- heterogenity (1)
- heterosis (1)
- high throughput sequencing (1)
- histology (1)
- honey bees (1)
- host cells (1)
- host pathogen interactions (1)
- host-pathogen adaption (1)
- host-pathogen interaction (1)
- human african trypanosomiasis (1)
- human immune system (1)
- human immunodeficiency virus (1)
- human melanoma (1)
- humane Keimzellen (1)
- hybrid origin (1)
- hybridization (1)
- hybrids (1)
- hymenoptera (1)
- hypotonic (1)
- hypotonic solutions (1)
- hypoxia-independent (1)
- hämatopoetisches Mosaik (1)
- illumina MiSeq platform (1)
- illumination microscopy (1)
- imaginal disk (1)
- immune escape (1)
- immune system (1)
- immuno-magnetic purification (1)
- immunological cross-talk (1)
- immunoprecipitation (1)
- import (1)
- in vivo (1)
- infection (1)
- insect (1)
- insect populations (1)
- insect timing (1)
- instinct (1)
- integrative genomics viewer (1)
- interolog (1)
- intracellular bacteria (1)
- intracellular pH (1)
- intracellular replication (1)
- isotonic (1)
- isotopolog profiling (1)
- kappa-B (1)
- key innovation (1)
- land use intensification (1)
- land-use intensity (1)
- landscape ecology (1)
- learning (1)
- learning and memory (1)
- life span (1)
- ligand CD55 (1)
- ligand-receptor complex (1)
- linkage map (1)
- long-distance dispersal (1)
- mRNA metabolism (1)
- maize (1)
- male-specific traits (1)
- males emerge (1)
- managed grasslands (1)
- management (1)
- mating success (1)
- melanogenesis (1)
- melanoma cells (1)
- membrane potential (1)
- membrane receptor signaling (1)
- memory (1)
- memory immune responses (1)
- metaanalysis (1)
- metagenomic (1)
- metastasis (1)
- metastatic melanoma (1)
- mice (1)
- microbial rhodopsins (1)
- mitochondria (1)
- mitochondrial membrane (1)
- models (1)
- modulates virulence (1)
- molecular cloning (1)
- monoclonal antibodies (1)
- morphogenetic furrow progression (1)
- mortality rates (1)
- moths and butterflies (1)
- motor proteins (1)
- mouse model (1)
- mouse testis differentiation (1)
- multi-electrode-recording (1)
- multiparticle collision dynamics (1)
- mutants (1)
- mutation (1)
- native bees (1)
- natural enemies (1)
- natural variation (1)
- nectar (1)
- nesting behaviour (1)
- network inference (1)
- networks (1)
- neuromuscular junction (1)
- neurons (1)
- nitric oxide (1)
- nonhuman-primates (1)
- normal distribution (1)
- norway spruce (1)
- nuclear envelope (1)
- nuclear pore complex (1)
- nucleotide-gated channel (1)
- odorants (1)
- oilseed rape (1)
- oncogene amplification (1)
- oncogene-induced senescence (1)
- oncolytic virotherapy (1)
- oncolytic virus therapy (1)
- onkolytische Virustherapie (1)
- optical control (1)
- optical reconstruction microscopy (1)
- organismal evolution (1)
- orthoptera (1)
- osmia (1)
- outer membrane proteins (1)
- ovarian cancer (1)
- ovarian carcinoma (1)
- p38 (1)
- painful (1)
- palynolog (1)
- parasites (1)
- patch connectivity (1)
- pathogen vacuole (1)
- pathogen-host interaction (PHI) (1)
- pathogenicity (1)
- pathways (1)
- performance liquid chromatography (1)
- permeability (1)
- peroxiredoxin 6 (1)
- pest (1)
- pestis infection (1)
- phagosome maturation arrest (1)
- phenology shifts (1)
- phenotypic plasticity (1)
- pheromones (1)
- phosphorylation (1)
- photodynamic therapy (1)
- physiological constraints (1)
- plant diversity (1)
- plant-insect interactions (1)
- plantations (1)
- pneumonic plague (1)
- poeciliid fishes (1)
- pollen (1)
- pollination (1)
- pollination ecology (1)
- populations (1)
- populations genetics (1)
- potential role (1)
- preexisting bias (1)
- preproteins (1)
- presynaptic calcium (1)
- presynaptic differentiation (1)
- principal component analysis (1)
- productivity (1)
- prognostic marker (1)
- proportion of seminatural habitat (1)
- propulsion (1)
- prostaglandin E2 (1)
- protandry (1)
- protein biosynthesis & quality control (1)
- protein complexes (1)
- protein domains (1)
- protein interaction database (1)
- protein interactions (1)
- protein-coupled receptors (1)
- protein-protein interaction (1)
- protein-protein interaction network (1)
- proteomics (1)
- quantification (1)
- rare (1)
- re-annotation (1)
- reactive oxygen (1)
- reactive oxygen species (1)
- recognize images (1)
- recombinant protein rVE (1)
- reconstruction microscopy (1)
- regulation (1)
- regulatory networks (1)
- reporter gene (1)
- resin (1)
- resolution (1)
- retinal differentiation (1)
- reveals (1)
- rhodopsin (1)
- ribosome (1)
- sand dynamics (1)
- secondary rainforest fragments (1)
- sequence alignment (1)
- sequencing data (1)
- serum (1)
- sex chromosome evolution (1)
- sex combs (1)
- sex differentiation (1)
- shear stress (1)
- shootin-1 (1)
- signals (1)
- similarity (1)
- size dimorphism (1)
- skin (1)
- small-colony variants (1)
- snoRNA (1)
- software (1)
- somatic mutations (1)
- specialization (1)
- species richness (1)
- spectrometry-based proteomics (1)
- sperm head formation (1)
- spermatogenesis (1)
- spermiogenesis (1)
- spillover (1)
- spire (1)
- spot size (1)
- stage III (1)
- statistical disperison (1)
- statistics (1)
- strategy (1)
- structure-function relationships (1)
- structured illumination (1)
- substrate quality (1)
- sucrose (1)
- super-resolution microscopy (1)
- sustainable intensification (1)
- swordtails (1)
- synaptic delay (1)
- synaptic transmission (1)
- synaptotagmin (1)
- t-Test (1)
- tag fusion proteins (1)
- tegument protein pUL36 (1)
- teleostei (1)
- temperature (1)
- tonicity (1)
- transcription (1)
- transcription factors (1)
- transcriptional regulation (1)
- transcriptional responses (1)
- transcriptome (1)
- transfer (1)
- transformation (1)
- translational regulation (1)
- trees (1)
- trophic interactions (1)
- tsetse fly (1)
- tumor vascularization (1)
- tumors (1)
- turnover (1)
- type-1 (1)
- ubiquitination (1)
- vaccine (1)
- vaccinia virus (1)
- validation (1)
- variants (1)
- virotherapy (1)
- vision (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (98) (remove)
Sonstige beteiligte Institutionen
ResearcherID
- D-1221-2009 (1)
- N-2030-2015 (1)
Background
Defence mechanisms of organisms are shaped by their lifestyle, environment and pathogen pressure. Carpenter ants are social insects which live in huge colonies comprising genetically closely related individuals in high densities within nests. This lifestyle potentially facilitates the rapid spread of pathogens between individuals. In concert with their innate immune system, social insects may apply external immune defences to manipulate the microbial community among individuals and within nests. Additionally, carpenter ants carry a mutualistic intracellular and obligate endosymbiotic bacterium, possibly maintained and regulated by the innate immune system. Thus, different selective forces could shape internal immune defences of Camponotus floridanus.
Results
The immune gene repertoire of C. floridanus was investigated by re-evaluating its genome sequence combined with a full transcriptome analysis of immune challenged and control animals using Illumina sequencing. The genome was re-annotated by mapping transcriptome reads and masking repeats. A total of 978 protein sequences were characterised further by annotating functional domains, leading to a change in their original annotation regarding function and domain composition in about 8 % of all proteins. Based on homology analysis with key components of major immune pathways of insects, the C. floridanus immune-related genes were compared to those of Drosophila melanogaster, Apis mellifera, and other hymenoptera. This analysis revealed that overall the immune system of carpenter ants comprises many components found in these insects. In addition, several C. floridanus specific genes of yet unknown functions but which are strongly induced after immune challenge were discovered. In contrast to solitary insects like Drosophila or the hymenopteran Nasonia vitripennis, the number of genes encoding pattern recognition receptors specific for bacterial peptidoglycan (PGN) and a variety of known antimicrobial peptide (AMP) genes is lower in C. floridanus. The comparative analysis of gene expression post immune-challenge in different developmental stages of C. floridanus suggests a stronger induction of immune gene expression in larvae in comparison to adults.
Conclusions
The comparison of the immune system of C. floridanus with that of other insects revealed the presence of a broad immune repertoire. However, the relatively low number of PGN recognition proteins and AMPs, the identification of Camponotus specific putative immune genes, and stage specific differences in immune gene regulation reflects Camponotus specific evolution including adaptations to its lifestyle.
Staphylococcus aureus is a facultative Gram-positive human pathogen which can cause different severe infections. Staphylococci are phagocytosed by professional and non-professional phagocytes; they are strongly cytotoxic against eukaryotic cells and have been proposed to play a role in immune evasion by spreading within migrating phagocytes. This study investigated the post invasive events upon S. aureus infection. Strains which are able to escape the phagosome were identified and the responsible toxins were determined. Thereby innovative insights into host pathogen interaction were obtained.
A novel class of small amphipathic peptides with strong surfactant-like properties, the phenol soluble modulins, particularly PSMα as well as the leukocidin LukAB, are involved in phagosomal escape of the clinical S. aureus strains LAC, MW2 and 6850 in non-professional and professional phagocytes. Whereas, PSMβ, δ-toxin, α-toxin, β-toxin or phosphatidyl inositol-dependent phospholipase C did not affect phagosomal escape. By blocking the bacterial DNA-dependent RNA polymerase with rifampicin phagosomal escape is determined to start approximately 2.5 hours post infection. Phagosomal escape further was required for intracellular replication of S. aureus. Strains which are not able to escape cannot replicate in the acidic vacuole, whereas, the host cytoplasm offers a rich milieu for bacterial replication. Additionally, phagosomal escape, with intracellular bacterial replication induces the subsequent host cell death. This could be confirmed by an infection assay including S. aureus knockout mutants in psmα or lukAB which were significantly less cytotoxic, compared with those infected with escape-positive wild type strains.
Further, this study showed that phagosomal escape is not only mediated by bacterial toxins. Since, the phagocyte-specific cognate receptors for both escape relevant toxins, FPR2 (PSMα receptor) and CD11b (LukAB receptor) are produced in epithelial and endothelial cells only after infection with S. aureus in a calcium dependent fashion. The knockdown of both receptors using siRNA prevents S. aureus to escape the phagosome. Furthermore, blocking intracellular calcium release with the inositol trisphosphate receptor (IP3R) inhibitor 2-APB prohibits upregulation of fpr2 and cd11b and subsequently phagosomal escape of S. aureus.
To conclude, the current study clarifies that phagosomal escape and host cell death are interplay of both, bacterial toxins and host cell factors.
Staphylococcus aureus ist ein fakultativ Gram-positives Humanpathogen, dass verschiedene schwerwiegende Infektionen verursachen kann. Staphylokokken werden von professionellen und nicht-professionellen Phagozyten (Fresszellen) zu gleich aufgenommen. Desweitern sind sie stark zytotoxisch für eukaryotische Zellen. Außerdem wird vermutet, dass sie sich mittels migrierender Phagozyten dem angeborenen Immunsystem entziehen können. In dieser Studie werden die post-invasiven Ereignisse während einer Staphylokokken Infektion untersucht. Im Detail wurden Stämme identifiziert die aus den Phagosomen entkommen können und die dafür verantwortlichen Toxine. Im Zuge dessen wurden neue Erkenntnisse der Interaktion zwischen Bakterien und Wirtszellen gewonnen.
Eine neue Klasse von kleinen amphiphatischen Peptiden mit starken grenzflächenaktiven Eigenschaften (Surfactant), die sogenannten Phenol soluble modulins (PSMs) im Besonderen PSMα sowie das Leukozidin LukAB, sind am phagosomalen Ausbruch der klinisch relevanten S. aureus Stämmen LAC, MW2 und 6850 in nicht professionellen und professionellen Phagozyten involviert. Hingegen, sind PSMβ, δ-toxin, α-toxin, β-toxin oder Phosphatidylinositol abhängige Phospholipase C nicht am phagosomalen Ausbruch beteiligt. Durch die Hemmung der bakteriellen DNA-abhängigen RNA Polymerase mit Rifampicin wurde der Zeitpunkt für den Ausbruch auf etwa 2,5 Stunden nach der Infektion eingegrenzt. Der phagosomale Ausbruch ist weiterhin für die intrazelluläre Replikation von S. aureus notwendig. Während Stämme, die nicht ausbrechen können in der angesäuerten Vakuole nicht replizieren können, bietet das Zytoplasma ein reichhaltiges Milieu für die Vermehrung. Zudem wird der Pathogen induzierte Zelltod erst nach dem phagosomalen Ausbruch und mit anschließender Vermehrung ermöglicht. Nachgewiesen wurde dies mittels psmα und lukAB defizienten Mutanten welche signifikant weniger zytotoxisch waren als der Wildtyp Stamm. Diese Studie zeigt darüber hinaus, dass der phagosomale Ausbruch nicht nur durch bakterielle Toxine vermittelt wird. Sondern, dass die Phagozyten-spezifischen Rezeptoren für beide relevanten Toxine, FPR2 (PSMα Rezeptor) und CD11b (LukAB Rezeptor), in Epithel- und Endothelzellen nach Infektion mit S. aureus calciumabhängig produziert werden und für den Ausbruch notwendig sind. Der knockdown beider Rezeptoren mittels siRNA verhindert den Ausbruch. Wird der intrazelluläre Calciumstrom mittels des Inositoltrisphosphat Rezeptor (IP3R) Inhibitor 2-APB blockiert können die Gene fpr2 und cd11b nicht hochreguliert werden und der Ausbruch wird ebenfalls verhindert.
Folglich zeigt diese Studie, dass der phagosomale Ausbruch und Pathogen induzierte Zelltod sowohl durch bakterielle Toxine als auch Wirtsfaktoren vermittelt wird.
Immunity, Inflammation and Cancer: The role of Foxp3, TLR7 and TLR8 in gastrointestinal cancer
(2015)
Regulatory T cells (Treg) expressing the transcription factor forkhead box protein P3 (Foxp3) have been demonstrated to mediate evasion from anti-tumor immune responses during tumor progression. Moreover, Foxp3 expression by tumor cells themselves may allow them to counteract effector T cell responses, resulting in a survival benefit of the tumor. For gastrointestinal cancers, in particular pancreatic and colorectal cancer (CRC), the clinical relevance of Foxp3 is not clear to date. Therefore the aim of this study was to analyze its impact in CRC and pancreatic cancer. To determine the relevance of Foxp3 for tumor progression and patient survival, gene and protein analysis of human pancreatic and colon cancer cell lines as well as tumor tissues from patients with CRC was performed. The results derived from the patients with CRC were correlated with clinicopathological parameters and patients’ overall survival. Cancer cell mediated Foxp3 expression in vitro was demonstrated in human pancreatic cancer cell lines PANC1, PaCa DD 135, PaCa DD 159 and PaCa DD 185 as well as in human colon cancer cell lines SW480 and SW620. Additionally, Foxp3 expressing cancer cells were found in ex vivo tumor tissue samples of patients with CRC. The percentage of Foxp3+ cancer cells increased from stages UICC I/II to UICC III/IV compared to normal tissue. Moreover, high tumor cell mediated Foxp3 expression was associated with poor prognosis compared to patients with low Foxp3 expression. In contrast, low and high Foxp3 level in tumor infiltrating Treg cells demonstrated no significant differences in patients’ overall survival. Correlation analysis demonstrated a significant association of Foxp3 cancer cell expression with the expression of immunosuppressive cytokines IL-10 and TGF-β. These findings suggest that Immunosuppressive cytokines such as IL-10 and TGF-β released by rather Foxp3+ cancer cells than Foxp3+ Treg cells may inhibit the activation of naive T cells, hence limiting antitumor immune responses and favoring tumorigenesis and progression.
Chronic inflammation has been shown to be an important epigenetic and environmental factor in numerous tumor entities. Recent data suggest that tumorigenesis and tumor progression may be associated with inflammation-triggered activation of Toll-like receptors (TLR). In this study, the specific impact of both TLR7 and TLR8 expression and signaling on tumor cell proliferation and chemoresistance is analyzed in inflammation linked CRC and pancreatic cancer. By gene and protein expression analysis of human pancreatic and colon cancer cell lines TLR7 and TLR8 expression was determined in vitro. Additionally, expression of TLR7/TLR8 in UICC stage I-IV pancreatic cancer, chronic pancreatitis and normal pancreatic tissue was examined. For in vitro/in vivo studies TLR7/TLR8 overexpressing PANC1 cell lines were generated and analyzed for effects of TLR expression and stimulation on tumor cell proliferation and chemoresistance. Cancer cell mediated TLR7 and TLR8 expression in vitro was demonstrated in human colon cancer cell lines SW480, SW620 and HT-29 as well as in primary pancreatic cancer cell lines PaCa DD 135, PaCa DD 159 and PaCa DD 185. Additionally, TLR7 and TLR8 expressing tumor cells were found in ex vivo tissue samples of patients with pancreatic cancer and chronic pancreatitis. Significantly elevated expression levels of TLR7 and TLR8 were found in advanced tumor stages (UICC III) compared to early tumor stages (UICC II) and chronic pancreatitis. No or occasionally low expression was detected in normal pancreatic tissue. In contrast to the tissues from patients with pancreatic cancer or chronic pancreatitis, established pancreatic tumor cell lines express only very low levels of TLR7 and TLR8. Therefore, for in vitro and xenograft studies TLR7 or TLR8 overexpressing PANC1 cells were generated. Proliferation promoting effects of TLR7 and TLR8 expression and stimulation with R848 were detected in vitro. Additionally, increased tumor growth of TLR expressing PANC1 cells was demonstrated in subcutaneously injected Balb/c nude mice. Interestingly, activation of TLR7 or TLR8 induced not only an increase in tumor cell proliferation but also a strong chemoresistance of PANC1 cells against 5-fluorouracil (5-FU). Moreover, treatment with R848 resulted in elevated expression levels of NF-κB, COX-2 and inflammatory cytokines IL-1β, IL-8 and TNF-α, suggesting TLR7/8 signaling to contribute to an inflammatory, anti-apoptotic and proliferation promoting tumor microenvironment. These findings emphasize the particular role of TLR7 and TLR8 in inflammation related cancers and their relevance as potential targets for cancer therapy.
Molecular and cellular cross talk between angiogenic, immune and DNA mismatch repair pathways
(2015)
VEGF is a main driver of tumor angiogenesis, playing an important role not only in the formation of new blood vessels, but also acts as a factor for cell migration, proliferation, survival and apoptosis. Angiogenesis is a universal function shared by most solid tumors and its inhibition was thought to have the potential to work across a broad patient population. Clinical evidence has shown that inhibiting pathological angiogenesis only works in a subset of patients and the identification of those patients is an important step towards personalized cancer care. The first approved antiangiogenic therapy was bevacizumab (Avastin®), a monoclonal antibody targeting VEGF in solid tumors including CRC, BC, NSCLC, RCC and others.
In addition to endothelial cells, VEGF receptors are present on a number of different cell types including tumor cells, monocytes and macrophages. The work presented in this thesis looked at the in vitro cellular changes in tumor cells and leukocytes in response to the inhibition of VEGF signaling with the use of bevacizumab. In the initial experiments, VEGF was induced by hypoxia in tumor cells to evaluate changes in survival, proliferation, migration and changes in gene or protein expression. There was a minimal direct response of VEGF inhibition in tumor cells that could be attributed to bevacizumab treatment, with minor variations in some of the cell lines screened but no uniform or specific response noted.
MMR deficiency often results in microsatellite instability (MSI) in tumors, as opposed to microsatellite stable (MSS) tumors, and accounts for up to 15% of colorectal carcinomas (CRCs). It has been suggested in clinical data that MMR deficient tumors responded better to bevacizumab regimens, therefore further research used isogenic paired CRC tumor cell lines (MMR deficient and proficient). Furthermore, a DNA damaging agent was added to the treatment regimen, the topoisomerase inhibitor SN-38 (the active metabolite of irinotecan). Inhibiting VEGF using bevacizumab significantly inhibited the ability of MMR deficient tumor cells to form anchor dependent colonies, however conversely, bevacizumab treatment before damaging cells with SN-38, showed a significant increase in colony numbers. Moreover, VEGF inhibition by bevacizumab pretreatment also significantly increased the mutation fraction in MMR deficient cells as measured by transiently transfecting a dinucleotide repeat construct, suggesting VEGF signaling may have an intrinsic role in MMR deficient cells. A number of pathways were analyzed in addition to changes in gene expression profiles resulting in the identification of JNK as a possible VEGF targeted pathway. JUN expression was also reduced in these conditions reinforcing this hypothesis, however the intricate molecular mechanisms remain to be elucidated.
In order to remain focused on the clinical application of the findings, it was noted that some cytokines were differentially regulated by bevacizumab between MMR proficient and deficient cells. Treatment regimens employed in vitro attempted to mimic the clinical setting by inducing DNA damage, then allowing cells to recover with or without VEGF using bevacizumab treatment. Inflammatory cytokines, CCL7 and CCL8, were found to have higher expression in the MMR deficient cell line with bevacizumab after DNA damage, therefore the cross talk via tumor derived factors to myeloid cells was analyzed. Gene expression changes in monocytes induced by tumor conditioned media showed CCL18 to be a bevacizumab regulated gene by MMR deficient cells and less so in MMR proficient cells. CCL18 has been described as a prognostic marker in gastric, colorectal and ovarian cancers, however the significance is dependent on tumor type. CCL18 primarily exerts its function on the adaptive immune system to trigger a TH2 response in T cells, but is also described to increase non-specific phagocytosis. The results of this study did show an increase in the phagocytic activity of macrophages in the presence of bevacizumab that was significantly more apparent in MMR deficient cells. Furthermore, after DNA damage MMR deficient cells treated with bevacizumab released a cytokine mix that induced monocyte migration in a bevacizumab dependent manner, showing a functional response with the combination of MMR deficiency and bevacizumab. In summary, the work in this thesis has shown evidence of immune cell modulation that is specific to MMR deficient tumor cells that may translate into a marker for the administration of bevacizumab in a clinical setting.
VEGF ist ein zentraler Regulator der Tumor-Angiogenese, und spielt eine wichtige Rolle nicht nur in der Bildung von neuen Blutgefäßen, sondern ist auch für die Migration, Proliferation, das Überleben und Apoptose von Tumorzellen essentiell. Angiogenese ist eine der universellen Funktionen, welche das Wachstum der meisten soliden Tumoren charakterisiert. Eine der klassischen therapeutischen Ideen wurde auf der Basis entwickelt, dass die spezifische Hemmung der Angiogenese das Potenzial hat in einer breiten Patientenpopulation einen klinischen Effekt zu zeigen. Die klinische Erfahrung und Anwendung hat jedoch gezeigt, dass die Hemmung der pathologischen Angiogenese nur in einem Teil der Patienten einen therapeutischen Nutzen aufweist. Somit stellt die Identifikation derjenigen Patienten, welche von der anti-angiogenen Therapie profitieren, einen wichtiger Schritt zur personalisierten Krebsbehandlung dar. Die erste zugelassene antiangiogene Therapie war Bevacizumab (Avastin®), ein monoklonaler Antikörper gegen VEGF, welcher unter anderem in soliden Tumoren wie CRC, BC, nicht-kleinzelligem Lungenkrebs (NSCLC) und dem Nierenzellkarzinom angewandt wird.
VEGF-Rezeptoren befinden sich nicht nur auf Endothelzellen, sondern sind auch auf einer Anzahl von verschiedenen Zelltypen, einschließlich Tumorzellen, Monozyten und Makrophagen nachweisbar. Die in dieser Arbeit vorgestellten Ergebnisse befassen sich mit den zellulären Veränderungen an Tumorzellen und Leukozyten als Reaktion auf die Hemmung der VEGF-Signalkaskade durch Bevacizumab in-vitro. In den Initialen Experimenten wurde VEGF durch Hypoxie in Tumorzellen induziert und Veränderungen der Überlebensrate, der Proliferation, Migration als auch in der Gen- oder Protein-Expression gemessen. Es konnte eine minimale direkte Reaktion der VEGF-Hemmung auf Tumorzellen beobachtet werden, welche auf die Bevacizumab Behandlung zurückgeführt werden könnte. Es zeigten sich aber auch geringfügige Abweichungen in einigen der verwendeten Zellinien, die keine einheitliche Interpretation erlauben oder auf eine uniformelle Reaktion hinweisen würden.
Das phänotypische Korrelat einer „Mismatch“ Reparatur (MMR)-Defizienz ist die Mikrosatelliteninstabilität im Gegensatz zu mikrosatellitenstabilen Tumoren und findet sich bei bis zu 15% der kolorektalen Karzinomen (CRC) wieder. Klinischen Daten deuten daraufhin, dass Bevacizumab besser in MMR-defizienten Tumoren wirkt. Daher wurden die weiteren Untersuchungen in gepaarten MMR stabilen und MMR instabilen CRC-Tumorzelllinien (MMR defizient und kompetent) durchgeführt. Weiterhin wurde ein DNA-schädigendes Agens, SN-38, ein Topoisomerase-Inhibitor (der aktive Metabolit von Irinotecan) dem Behandlungsschema zugefügt. Es zeigte sich, dass die Hemmung von VEGF mittels Bevacizumab die Fähigkeit der MMR defizienten Tumorzellen Kolonien zu bilden signifikant inhibiert. Im Gegensatz dazu, hatte die Behandlung von Bevacizumab vor der Zugabe des DNA schädigenden Agens zu einer vermehrten Kolonienzahl geführt. Außerdem erhöhte die Vorbehandlung mit Bevacizumab deutlich die Mutationsrate in MMR-defizienten Zellen, was durch die transiente Transfektion eines Dinukleotid-Repeat-Konstrukts nachgewiesen werden konnte. Dies deutete darauf hin, dass VEGF eine intrinsische Rolle in der Signalkaskade des MMR-Systems haben könnte. Deshalb wurde eine Anzahl von Signalalkaskaden zusätzlich zu Veränderungen von Genexpressionsprofilen untersucht und JNK als mögliche Verbindungsstelle der beiden Signalkaskaden, VEGF und MMR, identifiziert. Diese Hypothese wurde zusätzlich unterstützt durch die Tatsache, dass die JUN Expression unter diesen experimentellen Bedingungen reduziert war. Die Aufklärung der komplexen molekularen Mechanismen der potentiellen Interaktion bleibt zukünftigen Untersuchungen vorbehalten.
In Hinblick auf die klinische Konsequenz der erhaltenen Ergebnisse war es auffällig, dass einige Zytokine durch Bevacizumab in den MMR defizienten Zellen im Gegensatz zu den MMR kompetenten Zellen unterschiedlich reguliert wurden. Die in-vitro verwendeten Behandlungsschemata waren den klinisch zur Anwendung kommenden Protokollen nachempfunden. Zuerst wurde ein DNA-Schaden gesetzt, und den Zellen ermöglicht, sich mit oder ohne Bevacizumab zu erholen. Es konnte gezeigt werden, dass die inflammatorischen Zytokine CCL7 und CCL8 eine höhere Expression in der MMR-defiziente Zelllinie in Kombination mit Bevacizumab aufweisen. Daher wurde ein möglicher Crosstalk zwischen von Tumorzellen sezernierten Faktoren und myeloischen Zellen weiter verfolgt. Veränderungen der Genexpression in Monozyten durch Tumorzell- konditionierte Medien zeigte CCL18 als ein Bevacizumab reguliertes Gen in MMR-defizienten Zellen, aber nicht in MMR kompetenten Zellen. CCL18 übt seine Funktion primär im adaptiven Immunsystems aus um eine TH2-Antwort in T-Zellen auszulösen Ausserdem wird eine Erhöhung der nicht-spezifische Phagozytose als weitere Funktion beschrieben. CCL18 wurde bereits als prognostischer Marker in Magen-, Dickdarm- und Eierstockkrebsarten beschrieben; die klinische Bedeutung ist jedoch abhängig von Tumortyp.
Die Ergebnisse dieser Arbeit zeigen, dass eine Erhöhung der phagozytischen Aktivität von Makrophagen in Gegenwart von Bevacizumab wesentlich deutlicher in MMR-defizienten Zellen ausgeprägt war. Weiterhin wurde gefunden, dass nach DNA-Schädigung in Bevacizumab behandelten MMR-defizienten Zellen Zytokine freigesetzt werden, welche eine Monozytenmigration in einer Bevacizumab-abhängigen Weise induzieren. Dies weist auf eine funktionelle Interaktion von MMR-Defizienz und Bevacizumab hin. Zusätzlich zeigen die Ergebnisse dieser Arbeit eine Immunzellmodulation, die spezifisch für Mismatch-Reparatur defiziente Tumorzellen ist und in der klinischen Praxis als Marker für die Verabreichung von Bevacizumab verwendet werden könnte.
Tumor-induced angiogenesis is of major interest for oncology research. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor characterized so far. VEGF blockade was shown to be sufficient for angiogenesis inhibition and subsequent tumor regression in several preclinical tumor models. Bevacizumab was the first treatment targeting specifically tumor-induced angiogenesis through VEGF blockade to be approved by the Food and Drugs Administration (FDA) for cancer treatment. However, after very promising results in preclinical evaluations, VEGF blockade did not show the expected success in patients. Some tumors became resistant to VEGF blockade. Several factors have been accounted responsible, the over-expression of other angiogenic factors, the noxious influence of VEFG blockade on normal tissues, the selection of hypoxia resistant neoplastic cells, the recruitment of hematopoietic progenitor cells and finally the transient nature of angiogenesis inhibition by VEGF blockade. The development of blocking agents against other angiogenic factors like placental growth factor (PlGF) and Angiopoietin-2 (Ang-2) allows the development of an anti-angiogenesis strategy adapted to the profile of the tumor.
Oncolytic virotherapy uses the natural propensity of viruses to colonize tumors to treat cancer. The recombinant vaccinia virus GLV-1h68 was shown to infect, colonize and lyse several tumor types. Its descendant GLV-1h108, expressing an anti-VEGF antibody, was proved in previous studies to inhibit efficiently tumor induced angiogenesis. Additional VACVs expressing single chain antibodies (scAb) antibodies against PlGF and Ang-2 alone or in combination with anti VEGF scAb were designed.
In this study, VACV-mediated anti-angiogenesis treatments have been evaluated in several preclinical tumor models. The efficiency of PlGF blockade, alone or in combination with VEGF, mediated by VACV has been established and confirmed. PlGF inhibition alone or with VEGF reduced tumor burden 5- and 2-folds more efficiently than the control virus, respectively.
Ang-2 blockade efficiency for cancer treatment gave controversial results when tested in different laboratories. Here we demonstrated that unlike VEGF, the success of Ang-2 blockade is not only correlated to the strength of the blockade. A particular balance between Ang-2, VEGF and Ang-1 needs to be induced by the treatment to see a regression of the tumor and an improved survival. We saw that Ang-2 inhibition delayed tumor growth up to 3-folds compared to the control virus. These same viruses induced statistically significant tumor growth delays. This study unveiled the need to establish an angiogenic profile of the tumor to be treated as well as the necessity to better understand the synergic effects of VEGF and Ang-2. In addition angiogenesis inhibition by VACV-mediated PlGF and Ang-2 blockade was able to reduce the number of metastases and migrating tumor cells (even more efficiently than VEGF blockade).
VACV colonization of tumor cells, in vitro, was limited by VEGF, when the use of the anti-VEGF VACV GLV-1h108 drastically improved the colonization efficiency up to 2-fold, 72 hours post-infection. These in vitro data were confirmed by in vivo analysis of tumors. Fourteen days post-treatment, the anti-VEGF virus GLV-1h108 was colonizing 78.8% of the tumors when GLV-1h68 colonization rate was 49.6%. These data confirmed the synergistic effect of VEGF blockade and VACV replication for tumor regression.
Three of the tumor cell lines used to assess VACV-mediated angiogenesis inhibition were found, in certain conditions, to mimic either endothelial cell or pericyte functions, and participate directly to the vascular structure. The expression by these tumor cells of e-selectin, p-selectin, ICAM-1 and VCAM-1, normally expressed on activated endothelial cells, corroborates our findings. These proteins play an important role in immune cell recruitment, and there amount vary in presence of VEGF, PlGF and Ang-2, confirming the involvement of angiogenic factors in the immuno-modulatory abilities of tumors.
In this study VACV-mediated angiogenesis blockade proved its potential as a therapeutic agent able to treat different tumor types and prevent resistance observed during bevacizumab treatment by acting on different factors. First, the expression of several antibodies by VACV would prevent another angiogenic factor to take over VEGF and stimulate angiogenesis. Then, the ability of VACV to infect tumor cells would prevent them to form blood vessel-like structures to sustain tumor growth, and the localized delivery of the antibody would decrease the risk of adverse effects. Next, the blockade of angiogenic factors would improve VACV replication and decrease the immune-modulatory effect of tumors. Finally the fact that angiogenesis blockade lasts until total regression of the tumor would prevent the recovery of the tumor-associated vasculature and the relapse of patients.
Rhodopsins are membrane-embedded photoreceptors found in all major taxonomic kingdoms using retinal as their chromophore. They play well-known functions in different biological systems, but their roles in fungi remain unknown. The filamentous fungus Fusarium fujikuroi contains two putative rhodopsins, CarO and OpsA. The gene carO is light-regulated, and the predicted polypeptide contains all conserved residues required for proton pumping. We aimed to elucidate the expression and cellular location of the fungal rhodopsin CarO, its presumed proton-pumping activity and the possible effect of such function on F. fujikuroi growth. In electrophysiology experiments we confirmed that CarO is a green-light driven proton pump. Visualization of fluorescent CarO-YFP expressed in F. fujikuroi under control of its native promoter revealed higher accumulation in spores (conidia) produced by light-exposed mycelia. Germination analyses of conidia from carO\(^{-}\) mutant and carO\(^{+}\) control strains showed a faster development of light-exposed carO-germlings. In conclusion, CarO is an active proton pump, abundant in light-formed conidia, whose activity slows down early hyphal development under light. Interestingly, CarO-related rhodopsins are typically found in plant-associated fungi, where green light dominates the phyllosphere. Our data provide the first reliable clue on a possible biological role of a fungal rhodopsin.
Cyclic GMP (cGMP) signalling regulates multiple biological functions through activation of protein kinase G and cyclic nucleotide-gated (CNG) channels. In sensory neurons, cGMP permits signal modulation, amplification and encoding, before depolarization. Here we implement a guanylyl cyclase rhodopsin from Blastocladiella emersonii as a new optogenetic tool (BeCyclOp), enabling rapid light-triggered cGMP increase in heterologous cells (Xenopus oocytes, HEK293T cells) and in Caenorhabditis elegans. Among five different fungal CyclOps, exhibiting unusual eight transmembrane topologies and cytosolic N-termini, BeCyclOp is the superior optogenetic tool (light/dark activity ratio: 5,000; no cAMP production; turnover (20 °C) ~17 cGMPs\(^{-1}\)). Via co-expressed CNG channels (OLF in oocytes, TAX-2/4 in C. elegans muscle), BeCyclOp photoactivation induces a rapid conductance increase and depolarization at very low light intensities. In O\(_2\)/CO\(_2\) sensory neurons of C. elegans, BeCyclOp activation evokes behavioural responses consistent with their normal sensory function. BeCyclOp therefore enables precise and rapid optogenetic manipulation of cGMP levels in cells and animals.
Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally referred to as 'accidental cell death' (ACD). In most settings, however, cell death is initiated by a genetically encoded apparatus, correlating with the fact that its course can be altered by pharmacologic or genetic interventions. 'Regulated cell death' (RCD) can occur as part of physiologic programs or can be activated once adaptive responses to perturbations of the extracellular or intracellular microenvironment fail. The biochemical phenomena that accompany RCD may be harnessed to classify it into a few subtypes, which often (but not always) exhibit stereotyped morphologic features. Nonetheless, efficiently inhibiting the processes that are commonly thought to cause RCD, such as the activation of executioner caspases in the course of apoptosis, does not exert true cytoprotective effects in the mammalian system, but simply alters the kinetics of cellular demise as it shifts its morphologic and biochemical correlates. Conversely, bona fide cytoprotection can be achieved by inhibiting the transduction of lethal signals in the early phases of the process, when adaptive responses are still operational. Thus, the mechanisms that truly execute RCD may be less understood, less inhibitable and perhaps more homogeneous than previously thought. Here, the Nomenclature Committee on Cell Death formulates a set of recommendations to help scientists and researchers to discriminate between essential and accessory aspects of cell death.
1. Zusammenfassung
Während der Embryogenese und nach Verletzungen von Nerven regulieren neurotrophe Faktoren Signalwege für Apoptose, Differenzierung, Wachstum und Regeneration von Neuronen. In vivo Experimente an neugeborenen Nagern haben gezeigt, dass der Verlust von Motoneuronen nach peripherer Nervenläsion durch die Behandlung mit GDNF, BDNF, und CNTF reduziert werden kann In der pmn-Mausmutante, einem Modell für die Amyotrophe Lateralsklerose, führt die Gabe von CNTF, nicht aber von GDNF zu einem verzögerten Krankheitsbeginn und einem verlangsamten Fortschreiten der Motoneuronendegeneration. Auslöser der Motoneuronendegeneration in der pmn-Maus ist eine Mutation im Tubulin spezifischen Chaperon E (Tbce) Gen, das für eines von fünf Tubulin spezifischen Chaperonen (TBCA-TBCE) kodiert und an der Bildung von -Tubulinheterodimeren beteiligt ist. Diese Arbeit sollte dazu beitragen, die CNTF-induzierten Signalwege zu entschlüsseln, die sich lindernd auf den progredienten Verlauf der Motoneuronendegeneration in der pmn-Maus auswirken.
Primäre pmn mutierte Motoneurone zeigen ein reduziertes Axonwachstum und eine erhöhte Anzahl axonaler Schwellungen mit einer anomalen Häufung von Mitochondrien - ein frühes Erkennungsmerkmal bei ALS-Patienten. Die Applikation von CNTF nicht aber von BDNF oder GDNF, kann in vitro die beobachteten Wachstumsdefekte und das bidirektionale axonale Transportdefizit in pmn mutierten Motoneurone verhindern.
Aus älteren Untersuchungen war bekannt, dass CNTF über den dreiteiligen transmembranen Rezeptorkomplex, bestehend aus CNTFR, LIFR und gp130, Januskinasen aktiviert, die STAT3 an Tyrosin 705 phosphorylieren (pSTAT3Y705). Ich konnte beobachten, dass axonales fluoreszenzmarkiertes pSTAT3Y705 nach CNTF-Gabe nicht retrograd in den Nukleus transportiert wird. Stattdessen führt die CNTF-induzierte Phosphorylierung von STAT3 an Tyrosin 705 zu einer transkriptionsunabhängigen lokalen Reaktion im Axon. Diese pSTAT3Y705 abhängige Reaktion ist notwendig und ausreichend, um das reduzierte Axonwachstum pmn mutierter Motoneurone zu beheben. Wie die Kombination einer CNTF Behandlung mit dem shRNA vermittelten knock-down von Stathmin in pmn mutierten Motoneuronen zeigt, zielt die CNTF-STAT3 Signalkaskade auf die Stabilisierung axonaler Mikrotubuli ab und wirkt sich positiv auf die anterograde und retrograde Mobilität von axonalen Mitochondrien aus.
Interessanter Weise konnte ich außerdem feststellen, dass eine akute Gabe von CNTF das mitochondriale Membranpotential in Axonen primärer pmn mutierter und wildtypischer
Motoneurone erhöht und einen Anstieg von ATP auslöst. Meine Beobachtungen legen nahe, dass CNTF unerwarteter Weise auch eine transiente Phosphorylierung an STAT3 Serin 727 (pSTAT3S727) auslöst, die zur anschließenden Translokation von pSTAT3S727 in Mitochondrien führt. Diese Ergebnisse zeigen, dass STAT3 mehrere lokale Ziele im Axon besitzt, nämlich axonale Mikrotubuli und Mitochondrien.
The pro-apoptotic Bcl-2-family protein Bim belongs to the BH3-only proteins known as initiators of apoptosis. Recent data show that Bim is constitutively inserted in the outer mitochondrial membrane via a C-terminal transmembrane anchor from where it can activate the effector of cytochrome c-release, Bax. To identify regulators of Bim-activity, we conducted a search for proteins interacting with Bim at mitochondria. We found an interaction of Bim with Tom70, Tom20 and more weakly with Tom40, all components of the Translocase of the Outer Membrane (TOM). In vitro import assays performed on tryptically digested yeast mitochondria showed reduced Bim insertion into the outer mitochondrial membrane (OMM) indicating that protein receptors may be involved in the import process. However, RNAi against components of TOM (Tom40, Tom70, Tom22 or Tom20) by siRNA, individually or in combination, did not consistently change the amount of Bim on HeLa mitochondria, either at steady state or upon de novo-induction. In support of this, the individual or combined knockdowns of TOM receptors also failed to alter the susceptibility of HeLa cells to Bim-induced apoptosis. In isolated yeast mitochondria, lack of Tom70 or the TOM-components Tom20 or Tom22 alone did not affect the import of Bim into the outer mitochondrial membrane. In yeast, expression of Bim can sensitize the cells to Bax-dependent killing. This sensitization was unaffected by the absence of Tom70 or by an experimental reduction in Tom40. Although thus the physiological role of the Bim-TOM-interaction remains unclear, TOM complex components do not seem to be essential for Bim insertion into the OMM. Nevertheless, this association should be noted and considered when the regulation of Bim in other cells and situations is investigated.